These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 19593660

  • 1. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [Abstract] [Full Text] [Related]

  • 2. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
    Chamberlain MC, Johnston S.
    J Neurooncol; 2009 Feb; 91(3):359-67. PubMed ID: 18953491
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC, Johnston S.
    Cancer; 2009 Apr 15; 115(8):1734-43. PubMed ID: 19197992
    [Abstract] [Full Text] [Related]

  • 4. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC, Kim BT.
    J Neurooncol; 2017 Jul 15; 133(3):561-569. PubMed ID: 28500559
    [Abstract] [Full Text] [Related]

  • 5. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2011 May 15; 102(3):427-32. PubMed ID: 20680397
    [Abstract] [Full Text] [Related]

  • 6. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC, Tsao-Wei DD.
    Cancer; 2004 Mar 15; 100(6):1213-20. PubMed ID: 15022289
    [Abstract] [Full Text] [Related]

  • 7. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I.
    Med Oncol; 2015 Feb 15; 32(2):460. PubMed ID: 25572814
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Salvage therapy with single agent bendamustine for recurrent glioblastoma.
    Chamberlain MC, Johnston SK.
    J Neurooncol; 2011 Dec 15; 105(3):523-30. PubMed ID: 21626071
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
    Kaloshi G, Brace G, Rroji A, Bushati T, Roci E, Hoxha M, Fejzo G, Petrela M.
    Tumori; 2013 Dec 15; 99(5):601-3. PubMed ID: 24362864
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
    Arakawa Y, Mizowaki T, Murata D, Fujimoto K, Kikuchi T, Kunieda T, Takahashi JC, Takagi Y, Miyamoto S.
    Neurol Med Chir (Tokyo); 2013 Dec 15; 53(11):779-85. PubMed ID: 24140770
    [Abstract] [Full Text] [Related]

  • 20. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH, Shen YL, Keegan P, Pazdur R.
    Oncologist; 2009 Nov 15; 14(11):1131-8. PubMed ID: 19897538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.